<DOC>
	<DOCNO>NCT02626845</DOCNO>
	<brief_summary>This phase IV , single-center , randomize , placebo-controlled pilot study evaluate efficacy rituximab induce otolaryngologic remission GPA patient active otolaryngologic disease .</brief_summary>
	<brief_title>Rituximab Otolaryngologic Manifestations Granulomatosis With Polyangiitis</brief_title>
	<detailed_description>Patients GPA active ENT disease least two ENT domain , define endoscopic visualization upper airway audiometric evaluation single otolaryngologist use validated GPA ENT disease activity score , eligible inclusion . ENT disease may new , grumble relapse . All patient enter trial receive standard induction therapy rituximab ( 375mg/m2 per week x 4 ) . At week 16 , patient randomize receive maintenance rituximab ( 1000mg ) every 4 month placebo infusion . The primary outcome assess week 52 . Patients treat standardized prednisone taper accord whether severe limited disease study entry , prednisone taper complete week 16 . The investigator plan enroll 28 patient randomize 1:1 fashion rituximab placebo . The investigator estimate accrual subject take 18 month study initiation . Once enrol , subject follow 52 week primary endpoint assess .</detailed_description>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>GPA Specific Inclusion : 1 . Patients must meet least 2 5 modify ACR classification criterion GPA . These need present time study entry . The modified ACR criterion : Nasal oral inflammation , define development painful painless oral ulcer purulent bloody nasal discharge Abnormal chest radiograph , define presence nodule , fix infiltrates , cavity Active urinary sediment , define microscopic hematuria ( &gt; 5 red blood cell per high power field ) red blood cell cast Granulomatous inflammation biopsy , define histologic change show granulomatous inflammation within wall artery perivascular extravascular area ( artery arteriole ) Positive antineutrophil cytoplasmic antibody ( ANCA ) test specific proteinase3 , measure enzymelinked immunoassay 2 . Active GPA ENT domain within 1 month prior screening , active disease define score ≥2 GPA ENT disease activity score ( 7 item score 1= present 0= absent ) perform direct endoscopic visualization upper airway audiometric evaluation single expert otolaryngologist . Items include GPA ENT disease activity score : Bloody rhinorrhea ( Daily blood stain nasal discharge ) Objective stridor ( Stridor assess doctor ) Inflammation nasal examination ( Ulcers , granulation , friable mucosa rigid nasendoscopy . Excluding crust ) Inflammation flexible laryngoscopy ( Ulcers , granulation , friable mucosa larynx ) Inflamed TM*/middle ear ( Persistent inflammation granulation tissue tympanic membrane/middle ear ) Sudden sensorineural hearing loss ( 30db drop 3 frequency within 72 hour ) Other ENT/upper airway manifestation active GPA observe structured ENT exam include limited lacrimal gland dacryocystitis endobronchial disease General Medical Concerns : 3 . Age 18 old 4 . Willing able comply treatment followup procedures 5 . Men woman reproductive potential must agree use acceptable method birth control treatment twelve month completion treatment . 6 . Willing able provide write informed consent RituximabSpecific Concerns : ANC : &gt; 1000/mm3 Platelets : &gt; 100,000/mm3 Hemoglobin : &gt; 7 gm/dL Adequate renal function indicate Cr &gt; 4.0mg/dl Adequate liver function define AST ALT &lt; 2x Upper Limit Normal unless related primary disease . DiseaseSpecific Concerns : 1 . Creatinine &gt; 4.0mg/dl 2 . Respiratory failure require mechanical ventilatory support 3 . Previous treatment rituximab ( Rituxan® ) within 6 month screen 4 . History severe allergic anaphylactic reaction serious infusion reaction receive rituximab 5 . Failure respond previous course rituximab ( Rituxan® ) administer treatment GPA , determine discretion PI 5 . History severe allergic anaphylactic reaction humanize murine monoclonal antibody 6 . Use maintenance immunosuppressive agent ( methotrexate , azathioprine , mycophenolate mofetil leflunomide ) within 5 drug halflives prior baseline 7 . Treatment biologic agent , include belimumab , within past 3 month screen 8 . Treatment cyclophosphamide ( oral intravenous ) within past 1 month screen General Medical Concerns : Pregnancy ( negative serum pregnancy test perform woman childbearing potential within 7 day treatment ) , lactate . Inability comply study and/or followup procedure . RituximabSpecific Concerns : History HIV . Presence active infection.. New York Heart Association Classification III IV heart disease ( See Appendix D ) . Concomitant malignancy previous malignancy within last five year , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . History psychiatric disorder . At Investigator 's discretion , receipt live vaccine within 4 week prior randomization . Positive hepatitis B C serology consider potential exclusion criterion . Hepatitis B screen include hepatitis B surface antigen ( HBsAg ) core antibody ( antiHBc ) patient . For patient show evidence prior hepatitis B infection ( HBsAg positive [ regardless antibody status ] HBsAg negative antiHBc positive ) , consult physician expertise manage hepatitis B regard monitor consideration HBV antiviral therapy and/or Rituxan treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Granulomatosis Polyangiitis</keyword>
	<keyword>Wegener 's Granulomatosis</keyword>
	<keyword>GPA</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>ENT GPA</keyword>
</DOC>